For the quarter ending 2025-09-30, ARMP had $10,428K increase in cash & cash equivalents over the period. -$4,540K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -26,675 | -22,826 |
| Depreciation expense | 370 | 743 |
| Stock-based compensation expense | 622 | 1,356 |
| Change in fair value of the convertible loan | 14,643 | 548 |
| Non-cash interest expense | 4,341 | 7,398 |
| Change in right-of-use asset | -587 | -1,183 |
| Prepaid expenses and other assets | -1,018 | 1,173 |
| Accounts payable and accrued liabilities | 794 | -818 |
| Accrued compensation | 259 | -696 |
| Operating lease liability | -257 | -506 |
| Net cash used in operating activities | -4,298 | -14,791 |
| Purchases of property and equipment | 242 | 248 |
| Net cash used in investing activities | -242 | -248 |
| Proceeds from issuance of term debt, net of issuance costs | 15,000 | 10,000 |
| Payments for taxes related to net share settlement of equity awards | 32 | 14 |
| Net cash provided by financing activities | 14,968 | 9,986 |
| Net increase in cash, cash equivalents and restricted cash | 10,428 | -5,053 |
| Cash and cash equivalents at beginning of period | 14,771 | - |
| Cash and cash equivalents at end of period | 20,146 | - |
Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc. (ARMP)